Treatment strategies for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis: a narrative review Authors: Yi Yang, Yuhan Jiang, Tianyuchen Jiang, Hanyun Tu, Anping Su Published: 2026 ABSTRACT Background and ObjectiveUnilateral papillary thyroid carcinoma (PTC) with ipsilateral cervical lymph-node metastasis carries intermediate-to-high recurrence risk. Although total thyroidectomy is conventionally recommended by multiple clinical guidelines, accumulating real‑world evidence has triggered ongoing debates regarding surgical extent, neck dissection scope, adjuvant radioactive iodine administration and molecular‑guided risk stratification. This narrative review intends to synthesize contemporary clinical evidence and provide references for individualized therapeutic decision‑making for this specific patient population.MethodsLiterature was retrieved from PubMed, Embase, and Web of Science up to January 2026. English articles were screened by two reviewers through consensus. This is a narrative review without formal systematic-review procedures.Key Content and FindingsFor properly-selected patients, lobectomy provides similar oncological outcomes as total thyroidectomy with fewer complications. Unilateral central neck dissection plus selective lateral neck dissection balances tumour control and surgical morbidity. Aggressive pathological variants and concurrent B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E/telomerase reverse transcriptase (TERT) promoter dual mutations indicate elevated recurrence and mortality risk. Radioactive iodine (RAI) ablation ought to be determined by integrated risk assessment rather than routine application. Lymph‑node yield and lymph‑node ratio serve as key prognostic markers reflecting dissection quality and recurrence likelihood. Serum thyroglobulin, interfered by thyroglobulin antibodies, remains the core surveillance biomarker.ConclusionsRisk‑stratified individualized management is strongly recommended for unilateral PTC patients with ipsilateral cervical lymph‑node metastasis. This review may facilitate clinical practice. Nevertheless, most available evidence comes from retrospective studies; further high‑quality prospective investigations are required to refine treatment strategies. Introduction Papillary thyroid carcinoma (PTC), recognized as the most prevalent malignant neoplasm of the thyroid gland, typically exhibits a favorable prognosis. Nonetheless, in cases where the tumour metastasizes to the lateral cervical lymph nodes, corresponding to stage N1b, patients are categorized as having a moderate to high risk of recurrence in accordance with the guidelines established by the American Thyroid Association (ATA). As a result, their treatment strategies are accordingly escalated proactive (1). Currently, many countries continue to recommend that the preferred treatment for patients with unilateral PTC accompanied by lateral lymph node metastasis (LLNM) is total thyroidectomy (TT) (2-5). In recent years, with a more comprehensive understanding of PTC and advancements in diagnostic and treatment methodologies, the 'one-size-fits-all' approach to treatment has become progressively contentious. An increasing number of scholarly articles concentrate on comparing the efficacy of TT and thyroid lobectomy (LT), while also scrutinizing the necessity of radioactive iodine (RAI) therapy (1). Furthermore, the presence of high-risk factors such as occult lesions and aggressive pathological subtypes further complicates clinical decision-making. This article aims to synthesize recently published literature and conduct a comprehensive review of treatment strategies for unilateral PTC with unilateral LLNM, thereby offering valuable references for clinical practice. We present this article in accordance with the Narrative Review reporting checklist (available at https://gs.amegroups.com/article/view/10.21037/gs-2026-0281/rc). Methods This manuscript was designed as a narrative review. We performed targeted literature retrieval from PubMed, Embase, Web of Science, and Chinese databases, focusing on original studies, meta-analyses, and clinical practice guidelines published up to January 2026. Search keywords covered papillary thyroid carcinoma, ipsilateral lateral cervical lymph node metastasis, surgical extent, neck dissection, radioactive iodine ablation, and molecular biomarkers including B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E and telomerase reverse transcriptase (TERT) promoter mutation. Reference lists of relevant articles and guidelines were manually reviewed to capture additional potentially relevant publications. Two reviewers independently screened titles and abstracts, reviewed full-text articles, and selected literature for inclusion. Discrepancies were resolved through group consensus. The detailed literature retrieval setting, inclusion criteria are summarized in Table 1. Table 1The search strategy summaryItemsSpecificationDate of searchMarch 15, 2026; updated on July 20, 2026Databases and other sources searchedPubMed, Embase, Web of ScienceSearch terms usedPapillary thyroid carcinoma, ipsilateral lateral cervical lymph node metastasis, surgical extent, neck dissection, radioactive iodine ablation, and molecular biomarkers including BRAF V600E and TERT promoter mutationTimeframeInception to July 2026Inclusion criteriaPeer-reviewed, written in EnglishSelection processIndependently conducted by two authors (Y.Y. and T.J.) The search strategy summary Treatment strategies for patients with unilateral PTC accompanied by unilateral LLNM Extent of thyroidectomy Recommendations for TT in patients with PTC from Chinese and international guidelines Multiple international and domestic clinical guidelines have listed the indications for total thyroidectomy for PTC patients, as shown in Table 2. Table 2Guidelines for PTC patients undergoing TTGuidelinesDefinitionsAmerican Thyroid Association Management Guidelines [2025] (2)Tumour >4 cm (cT3a)Any size of gross extrathyroidal extension (cT3b or cT4)Clinical assessment of lymph node metastasis (cN1)Distant metastasis (cM1)National Comprehensive Cancer Network Clinical Practice Guidelines [2022] (3)Distant metastasis (cM1)Invasion of the surrounding tissues of the thyroid glandMaximum diameter of the primary lesion >4 cmAccompanied by obvious metastatic lymph nodes (cN1)Low differentiation typeHead and neck radiotherapy historyBilateral thyroid nodulesChina Anti-Cancer Association Guidelines [2025] (4)History of radiotherapy to the head and neck during childhoodMaximum diameter of the primary lesion >4 cmBilateral multiple cancer fociUnfavorable pathological subtypeRequires radioactive iodine therapy after surgeryWith lymph node metastasis in the lateral cervical region (cN1b)With gross extrathyroidal invasionEuropean Society for Medical Oncology Clinical Practice Guidelines [2019] (5)History of head and neck radiation exposureFamily history of thyroid cancerCytological invasive characteristicsMultiple cancer fociAssociated with extrathyroidal invasionClinical assessment of lymph node metastasis (cN1)Maximum diameter of the primary lesion >4 cmcM, clinical metastasis staging; cN, clinical node staging; cT, clinical tumor staging; PTC, papillary thyroid carcinoma; TT, total thyroidectomy. Guidelines for PTC patients undergoing TT cM, clinical metastasis staging; cN, clinical node staging; cT, clinical tumor staging; PTC, papillary thyroid carcinoma; TT, total thyroidectomy. Oncology prognosis For patients diagnosed with unilateral PTC accompanied by unilateral LLNM, the oncological prognosis associated with TT and LT serves as a fundamental basis for determining the appropriate surgical approach. In recent years, numerous retrospective studies and meta-analyses have been conducted to compare these surgical options. One such meta-analysis focusing on moderate-risk PTC with unilateral LLNM included eight studies comprising a total of 2,462 patients. The findings indicated that the recurrence-free survival (RFS) rate in the LT group was comparable to that of the TT group (1). Another meta-analysis also showed similar results. This article included 6 studies involving a total of 1,894 patients with unilateral PTC and unilateral LLNM. The results indicated that in terms of recurrence and RFS, the efficacy of LT and TT was comparable (6). Furthermore, numerous studies have demonstrated that in patients with screened unilateral PTC accompanied by ipsilateral lymph node metastasis, there exists no significant difference in overall survival (OS) rate and RFS between LT and TT (7,8). Saito et al. (9) conducted a 13-year follow-up study involving 401 patients with cN1b PTC. They also determined that, after adjustment using inverse probability of treatment weighting (IPTW), there were no statistically significant differences in the OS, RFS, and modified RFS between the LT group and the TT group. These findings collectively indicate that, in the absence of other high-risk factors, LT can attain equivalent oncological prognoses as TT. Safety and quality of life When the prognosis of tumors is similar, considerations such as the safety of surgical procedures, their influence on patients' quality of life, and the associated medical costs become pivotal in determining the extent of surgical intervention. Numerous studies consistently demonstrate that, in comparison with TT, LT offers notable advantages in terms of reduced complication rates and preservation of postoperative function (6). The risk of temporary and permanent hypoparathyroidism following TT is significantly higher than that observed after LT, primarily due to the wider surgical scope of TT, which may result in damage to both bilateral parathyroid glands and their blood supply (6,7,10,11). A prospective study, by monitoring the immediate postoperative levels of intact parathyroid hormone (iPTH), concluded that the risk of developing hypocalcemia following combined TT and central neck dissection (CND) was nearly 17 times higher than that associated with combined LT and CND (11). Furthermore, TT is also associated with a higher rate of temporary recurrent laryngeal nerve complications injury (6,10,12). These complications not only cause increased suffering for the patients but also elevate the complexity of postoperative management. Post-thyroidectomy thyroid stimulating hormone (TSH) suppression therapy necessitates the exogenous administration of levothyroxine; however, this may heighten the risks of coronary heart disease, stroke, osteoporosis, and other conditions. Patients with LT retain some thyroid function postoperatively, which leads to a lower dependence on levothyroxine and a reduced incidence of medication side effects (7,13,14). And LT is more likely to reduced incidence of medication side effects. Moreover, LT is more likely to achieve satisfactory control of TSH (15). In contrast, patients with TT are required to undergo lifelong medication and frequently face dosage modifications. Economic analysis indicates that the LT group experiences shorter hospital stays and incurs substantially lower overall hospitalization costs compared to the TT group (7). Furthermore, given that TT patients exhibit a greater incidence of permanent parathyroid dysfunction, the likelihood of requiring lifelong oral calcium and vitamin D supplementation is markedly higher compared to LT patients. Consequently, from both quality of life and economic perspectives, LT also presents a superior option. Hidden cancer foci in the contralateral thyroid lobe Among patients whose preoperative assessment indicated unilateral PTC, there may be undetected occult cancer foci in the contralateral lobe that were not identified through imaging, with an approximate incidence rate of 26.6% (16). This outcome directly influences the selection of the surgical scope, as LT may preserve cancerous lesions in the contralateral lobe, thereby increasing the risk of future recurrence or necessitating a secondary operation. Consequently, the identification of risk factors that predict the presence of occult malignant lesions in the contralateral lobe is essential for developing the initial surgical strategy. Various retrospective studies and meta-analyses have systematically examined these risk factors. The findings indicate that a primary tumor diameter exceeding 1 cm, a tumor location near or invading the isthmus, multifocal lesions within the ipsilateral lobe, the presence of benign imaging nodules in the contralateral lobe, and the existence of LLNM are independent predictors of occult malignant lesions in the contralateral lobe. Additionally, central lymph node metastasis has been confirmed to be significantly associated with occult malignant lesions in the contralateral lobe (16-18). In light of these high-risk factors, prediction models such as nomograms are capable of accurately estimating the likelihood of contralateral hidden cancer foci, achieving a relatively high accuracy rate [the area under the curve (AUC) value can exceed 0.9] (17,18). For high scores and multiple risk factors patients, even in the absence of contralateral gland lesions detected during preoperative examination, careful consideration should be given to performing TT to ensure a definitive cure and to prevent the necessity of a subsequent operation. Conversely, for low-risk patients, strict active surveillance of the healthy gland LT is a safe and feasible approach strategy (19). This personalized treatment decision, based on risk stratification, can ensure an optimal oncological prognosis while endeavoring to preserve thyroid function to the greatest extent possible. Efficacy of RAI following TT The primary objective of RAI therapy is to eradicate residual thyroid tissue and any microscopic metastatic foci post-surgery, thereby aiming to diminish the likelihood of disease recurrence. Nonetheless, in recent years, the clinical utility of RAI in patients with intermediate-risk PTC, particularly those with clinical N1b (cN1b), has been increasingly scrutinized. According to the latest guidelines from ATA, PTC patients with N1b disease are categorized into the intermediate‑to‑high‑risk or high‑risk recurrence groups. For patients at intermediate‑to‑high recurrence risk, RAI therapy may be considered on a case‑by‑case basis, whereas routine RAI administration is recommended for patients at high recurrence risk (2). NCCN guidelines provide more explicit recommendations: RAI therapy is a definite indication for N1b patients with persistently elevated post‑operative thyroglobulin (Tg) (>5–10 ng/mL) and evidence of residual lesions on ultrasonography or diagnostic whole‑body radioactive iodine scan (WBS) (3). Notably, all guidelines emphasize that “Response to Therapy Assessment” should serve as the basis for dynamically adjusting therapeutic strategies, rather than making a one‑time decision regarding RAI administration (20). A propensity‑score‑matched study from Samsung Medical Center in South Korea enrolled 2,198 N1b PTC patients. After a median follow‑up of 7.3 years, the 10‑year RFS rate was significantly higher in patients receiving RAI therapy than in those who did not (88.5 % vs. 78.9 %, P=0.002). Nevertheless, further subgroup analysis of this study demonstrated that the inter‑group difference lost statistical significance after excluding patients with minimal extrathyroidal extension (mETE) or post‑operative stimulated Tg >10 ng/mL (21). This finding indicates that the survival benefit in RFS conferred by RAI is largely confined to patient subgroups with higher‑risk features. A retrospective cohort study (N=1,036) from the Mayo Clinic further supported this conclusion. That study reported that the RFS benefit of RAI in N1b PTC was limited mainly to patients with post‑operative Tg >2 ng/mL and ≥3 metastatic lymph nodes; within this subgroup, RAI therapy reduced recurrence risk by up to 42 % (22). These findings underscore the importance of individualized therapeutic decision‑making guided by risk stratification. In contrast, data from Kuma Hospital in Japan showed that RAI therapy did not further reduce ipsilateral cervical recurrence rates among N1b patients who underwent thorough neck dissection (≥15 retrieved lymph nodes) and achieved undetectable post‑operative Tg levels (23). This observation suggests that when adequate surgical radicality is guaranteed, surgery may constitute the dominant prognostic determinant, and the incremental value of adjuvant RAI may be limited. A recent meta-analysis extensively examined this pertinent issue. This study incorporated eight investigations involving a total of 2,462 patients diagnosed with intermediate-risk PTC with unilateral LLNM. The subgroup analysis demonstrated that, when comparing lobectomy (LT) and TT combined with RAI therapy, there was no statistically significant difference observed in RFS. More critically, the comparison between patients who received LT or simple TT alone and those who received TT in conjunction with RAI therapy also revealed no significant difference in RFS. Additionally, the analysis indicated that for patients undergoing TT, the decision to add RAI therapy did not exert a significant impact on patient outcomes RFS (1). Horiuchi et al. (24) conducted a study on intermediate-risk PTC patients with cN1b and discovered that, irrespective of whether they received RAI treatment following TT, the five-year RFS was notably high. Even after applying propensity score matching (PSM), the difference continued to be statistically significant. Xu et al. (25)also observed in their PSM analysis of cN1b patients that individuals who underwent TT and RAI did not demonstrate a significant enhancement in RFS compared to the matched cohort that did not receive RAI. Consequently, for particular patients who do not intend to undergo RAI following surgery, LT may be considered a viable treatment alternative. Scope of lymph node dissection Central lymph nodes The extent of CND remains a long-standing controversial issue in the surgical management of PTC. Both the ATA guidelines and the NCCN guidelines specify that TT combined with therapeutic CND should be routinely performed for patients with clinically N1a (cN1a) differentiated thyroid carcinoma (DTC), in whom CNM has been preoperatively confirmed by ultrasonography and fine-needle aspiration cytopathology. The dissection scope uniformly covers lymphoadipose tissues of level Ⅵ and upper level Ⅶ, including the pretracheal region, bilateral tracheoesophageal grooves, and pararecurrent-laryngeal-nerve regions. Notably, the ATA guidelines further emphasize that bilateral CND is preferentially recommended in the setting of proven unilateral CNM to reduce the risks of contralateral occult metastasis and reoperation. For clinically N1b (cN1b) patients with concomitant LLNM, the ATA guidelines conditionally recommend concurrent ipsilateral CND, advising completion of ipsilateral CND during therapeutic. The NCCN guidelines align with the core principles of the ATA guidelines, stating explicitly that ipsilateral central-compartment lymph nodes should be completely dissected during LND for cN1b patients. If intraoperative evaluation raises strong suspicion of occult metastatic lesions in the contralateral central compartment, additional contralateral CND may be performed to achieve complete tumor resection. The scope of CND has persistently been a subject of debate within the surgical management of PTC. The primary focus revolves around the necessity of prophylactic CND (pCND) and the decision between conducting therapeutic CND unilaterally or bilaterally. For PTC cases with clinically negative lymph nodes (cN0), there remains no consensus regarding the routine implementation of this procedure pCND (26,27). Individuals who oppose pCND argue that this procedure does not substantially reduce the long-term recurrence rate; rather, it is associated with an increased risk of both transient and permanent hypoparathyroidism following surgery (28-30). However, supporters assert that pCND is capable of identifying occult central lymph node metastases and obtaining more precise pathological staging. Consequently, this may inform subsequent RAI therapy and potentially diminish the risk of recurrence (31,32). Furthermore, when conducting CND, for patients presenting with unilateral PTC, should one opt for unilateral CND (UCND) or bilateral CND (BCND)? Several studies have compared the prognosis and complications associated with UCND and BCND. The findings indicate that in patients with cN0 or cN1a unilateral PTC, there is no statistically significant difference in recurrence rates between the two surgical approaches; however, the incidence of temporary and permanent hypoparathyroidism is markedly higher in cases involving BCND group (33-35). Furthermore, certain studies have demonstrated that in patients presenting with unilateral positive lymph nodes in a clinical context, following solely therapeutic UCND, the likelihood of recurrence in the contralateral central region remains exceedingly low (approximately 1%) (36,37). Nevertheless, a retrospective study involving 695 patients with unilateral PTC combined with ipsilateral LLNM demonstrated that among all patients who underwent BCND, 52% (149 out of 286) presented with contralateral CNM. Multivariate regression analysis identified tumor diameter exceeding 2 cm, presence of ipsilateral CNM, and more than three LLNM as independent risk factors for contralateral CNM (38). Another study involved 708 patients with N1b stage who underwent TT combined with UCND, as well as TT with BCND and ipsilateral lateral neck dissection (LND). The results indicated that, among the 379 patients who received BCND, 34.6% developed contralateral CNM (37). Among patients with unilateral PTC and unilateral LLNM, BRAF V600E mutation status can assist in estimating the probability of occult CNM, thereby informing decisions regarding the extent of surgical dissection. Studies have demonstrated a synergistic effect between BRAF V600E mutation and multifocality. For patients with unilateral PTC harbouring both multifocality and the BRAF V600E mutation, the risk of CNM increases significantly; the relative excess risk due to interaction (RERI =4.323) indicates a synergistic interaction (39). These clinical evidences have prompted a re‑evaluation of therapeutic strategies for patients with unilateral PTC complicated by unilateral LLNM. Lateral neck lymph nodes For patients diagnosed with PTC with LLNM, the standard therapeutic approach involves undergoing a therapeutic LND. Typically, the conventional modified radical LND encompasses levels II–V. However, as our understanding of lymphatic metastasis patterns advances, the scope of LND is increasingly moving toward a personalized approach. Research indicates that in N1b PTC patients, the overall metastatic rate and occult metastasis rate in level V are relatively low, approximately 13.9% and 8.6% respectively, with recurrences in level V being correspondingly infrequent. Routine dissection of level V elevates the risk of complications, including ‘shoulder syndrome’, which manifests as shoulder dysfunction and pain. Furthermore, this study also identified that the concurrent presence of metastases in levels II, III, and IV markedly increases the risk of metastases in level V increases (40). Meanwhile, the contralateral CNM is also considered an independent risk factor for metastasis in level V (41). Based on these findings, for patients whose level V metastasis was not detected by preoperative imaging or intraoperative exploration, and who do not have high-risk factors such as multiple lateral neck nodes metastases, it is advisable to preserve the level V and only perform selective lateral neck nodes dissection for the levels II–IV. This approach can reduce surgical trauma and the incidence of complications without affecting the oncological prognosis. The metastasis of the level V is considered a high-risk factor for recurrence, suggesting that for patients with confirmed level V metastasis, more rigorous postoperative management should be implemented (42). Prognostic significance of lymph node yield (LNY) and the lymph node ratio (LNR) LNY and LNR, which is the quotient of positive lymph nodes to the total lymph nodes retrieved, serve as significant indicators for evaluating the quality of lymph node dissection and forecasting the likelihood of recurrence. Multiple retrospective cohort studies have demonstrated that LNY is associated with improved disease-specific survival (DSS) in patients with lymph-node-positive PTC. A SEER-database-based analysis revealed that LNY ≥10 was correlated with a lower long-term recurrence rate among pathologically node-negative PTC patients (43). Nevertheless, excessive dissection may raise the risk of complications including recurrent laryngeal nerve injury and hypoparathyroidism (44). Some studies have reported that LNY ≤3 during CND represents an independent adverse prognostic factor for central-compartment recurrence (45). Conversely, another study observed that increased LND may reduce recurrence risk only in N1b patients without gross extranodal extension (gENE), whereas no such benefit was seen in patients with gENE (46). These findings suggest that the prognostic value of LNY may be modulated by tumor biological behavior. Studies have shown that a high LNR strongly predicts poorer DFS (47-50). Optimal cut-off values for LNR vary across different investigations, ranging from 0.2 to 0.65, which may be attributable to differences in study populations, tumor subtypes and follow-up duration (46,51). Several studies have established that a higher LNY correlates with a reduced risk of recurrence rate (52,53). Several studies have suggested the minimum recommended number of lymph nodes to be dissected in the lateral cervical lymph nodes dissection for patients with N1b stage PTC. Specifically, for patients classified as T1–2 stage, a minimum of 34 lymph nodes should be identified, whereas for those in T3–4 stage, at least 46 lymph nodes should be examined to reduce the likelihood of residual disease lesions (52). LNR, as a comprehensive indicator that combines the number of metastatic lymph nodes and the extent of dissection, is considered a superior prognostic predictor in comparison to the mere count of positive lymph nodes. Numerous studies, including those focusing on both adult and pediatric PTC patients, have validated that LNR constitutes an independent risk factor for structural issues recurrence (10,54-56). Ji et al. (10) demonstrated that an LNR value exceeding 0.49 serves as a significant indicator of high risk for recurrence. Furthermore, in patients with T1 stage PTC exhibiting skip metastasis of lateral neck lymph nodes, the LNR also demonstrated robust prognostic discrimination ability (57). Therefore, these two indicators, LNY and LNR, can not only reflect the quality of the surgery but also provide an important basis for postoperative risk stratification and the formulation of individualized follow-up strategies. Clinical value of Tg and key mutational biomarkers Tg Tg is a large-molecular-weight glycoprotein synthesized by thyroid follicular cells. Among conventional serological biomarkers, Tg serves as the “gold standard” for monitoring postoperative recurrence or persistent disease in DTC. In the dynamic risk stratification (DRS) framework of the ATA guidelines, Tg levels are adopted as indicators of recurrence risk. Biochemical disease-free status is defined as suppressed Tg <0.2 ng/mL under thyrotropin-suppressive therapy or stimulated Tg <1.0 ng/mL, corresponding to a recurrence risk of <1% (3). Nevertheless, serum Tg monitoring has several important limitations. First, serum Tg concentrations are influenced by multiple factors, including the volume of residual thyroid tissue, the magnitude of TSH stimulation, interference from thyroglobulin antibodies (TgAb), and the differentiation status of tumor cells. Among these factors, the presence of TgAb represents one of the leading causes of unreliable serum Tg measurements. Studies have demonstrated that the positive rate of TgAb is markedly elevated (29.2–50.0%) in PTC patients with concurrent lymphocytic thyroiditis, and false-low or undetectable Tg results are frequently observed in this population (58). TgAb not only interferes with Tg immunoassays but also acts as an important prognostic factor for PTC. One study enrolling 1,122 PTC patients reported that preoperative TgAb >15 IU/mL was an independent predictor of PTC recurrence [hazard ratio (HR) =2.56]. Patients with TgAb >15 IU/mL combined with TPOAb ≤50 IU/mL exhibited the highest recurrence risk (HR =4.52) (59). Another large-sample study (N=4,434) proposed postoperative TgAb >440 IU/mL as a novel predictive biomarker for PTC recurrence, with an odds ratio of 6.0 (60). BRAF V600E/TERT promoter mutations BRAF V600E mutation is the most common driver genetic alteration in PTC and is strongly associated with aggressive histological subtypes, LNM, and increased recurrence risk (61,62). A meta-analysis comprising 69 studies with 14,170 PTC patients confirmed that this mutation significantly elevates tumor recurrence risk (OR =2.50, 95% CI: 1.73–3.59) (63). Another study of 9 908 PTC patients also demonstrated that BRAF V600E mutation is closely correlated with aggressive features including LNM [odds ratio (OR) =1.33], extrathyroidal extension (OR =1.61), and vascular invasion (OR =2.04), all of which represent critical drivers of tumor recurrence (64). TERT promoter mutations at C228T and C250T loci provide a novel dimension for risk stratification of PTC (65,66). They are significantly associated with adverse clinicopathological characteristics such as larger tumor size, extrathyroidal extension, and distant metastasis (67,68). This mutation serves as an independent adverse prognostic factor for DSS in PTC patients with positive LNM. Relevant studies have shown that TERT promoter mutation increases prognostic risk by 3- to 4-fold in PTC patients at high recurrence risk (69), and acts as an independent predictor of disease-specific death, with a hazard ratio as high as 9.34 after adjustment for other clinicopathological variables (70). TERT promoter mutations frequently co-occur with BRAF V600E mutation. Such “dual mutations” are correlated with high recurrence risk and elevated disease-specific mortality (71,72). A study enrolling 507 PTC patients reported that patients harboring both BRAF V600E and TERT C228T mutations exhibited a recurrence rate as high as 68.6%, substantially higher than the 8.7% observed in double-wild-type patients, with a hazard ratio of 8.51 (71). A large genetic-clinical correlation study of 1,051 patients clearly indicated that dual mutations exert a prominent synergistic amplifying effect on PTC-specific mortality, yielding a hazard ratio of 37.77, markedly higher than that of either single mutation (70). Meta-analyses have further validated that patients with dual mutations demonstrate far greater tumor aggressiveness than those with single mutations. On this basis, PTC can be stratified into four risk tiers, among which the dual-mutation subtype carries the highest risk (68,73). In addition, dual mutations are strongly linked to RAI resistance. The loss of RAI uptake reaches 97.4% in recurrent PTC patients with dual mutations, compared with only 30.2% in double-wild-type patients (74). Collectively, concurrent BRAF V600E and TERT promoter dual mutations constitute one of the molecular markers of high aggressiveness in PTC. Combined detection of these two markers bears substantial clinical implications for precise risk stratification, individualized therapeutic decision-making, and prognostic evaluation of PTC. Molecular biomarker testing plays an increasingly vital role in surgical extent decision-making and provides objective evidence for individualized management. Multiple studies have identified positive BRAF V600E mutation as an independent risk factor for predicting central-compartment lymph-node metastasis, and its positive predictive value and negative predictive value can guide the extent of surgery (75). When either BRAF V600E or TERT promoter mutation is detected, patients face substantially elevated recurrence risk. Under such circumstances, total thyroidectomy combined with therapeutic cervical LND is recommended to facilitate postoperative RAI therapy and more accurate Tg monitoring, so as to minimize recurrence risk (21,76). In contrast, for double-wild-type patients with unilateral tumors and absence of high-risk features including extrathyroidal extension and multifocality, a more conservative surgical strategy of lobectomy combined with functional neck dissection may be considered (1,25). BRAF V600E/TERT mutations and RAI resistance On post-RAI-whole-body iodine scan assessment, PTC with positive BRAF V600E mutation exhibits significantly lower RAI uptake compared with wild-type tumors, accompanied by markedly higher rates of incomplete biochemical response and incomplete structural response. A meta-analysis demonstrated that BRAF mutation increases the risk of RAI-refractory DTC by 3.60-fold, whereas the hazard ratio for TERT promoter mutation reaches as high as 9.84 (77). In clinical practice, patients with BRAF V600E-positive PTC are more prone to develop incomplete biochemical or structural responses after RAI therapy, manifested as persistently elevated serum Tg or radiologically detectable residual lesions (78). Studies have shown that TERT promoter mutations are strongly associated with distant metastasis, high-risk aggressive pathological features, and poor prognosis in PTC (67,68). The prevalence of TERT promoter mutations is substantially elevated in RAI-refractory PTC. These mutations frequently co-occur with BRAF V600E mutation, forming a “genetic duet” that jointly drives malignant progression and therapeutic resistance of tumors (78,79). A study of patients with RAI-refractory PTC reported that TERT promoter mutation was significantly correlated with the time to development of RAI refractoriness. The median time to RAI refractoriness was merely 0.7 months in mutation-positive patients, considerably shorter than 19.8 months observed in wild-type counterparts (80). Furthermore, TERT promoter mutations are closely linked to tumor necrosis, increased mitotic figures, and dedifferentiated histological variants (e.g., tall-cell variant and hobnail variant). These pathological features further impair the therapeutic efficacy of RAI (78,81). Impacts of special pathological types on treatment decisions Unilateral multifocal tumour The unilateral multifocality of tumors pertains to the presence of multiple cancerous lesions within a single side. Numerous studies have established that multifocality serves as an independent risk factor for CNM, and the incidence escalates proportionally with the increasing number of tumors foci (82-84). This finding indicates that, for patients with multifocal PTC, a comprehensive preoperative evaluation of lymph nodes should be performed regardless of tumor size, and pCND should be contemplated. Nevertheless, the extent to which multifocality elevates the risk of recurrence and mortality remains inconclusive, as research findings vary. Certain studies propose that, following adequate surgical management, the recurrence and survival rates of multifocal PTC are comparable to those observed in unifocal PTC (82). However, a meta-analysis has indicated that patients with unilateral multifocal PTC exhibit a higher incidence of lymph node metastasis, an advanced TNM stage, and an increased risk of recurrence compared to those with single-focal disease PTC (83). Therefore, individualized management should be implemented for patients with multifocal PTC. The treatment plan should be formulated based on the characteristics of the cancer foci, the results of lymph node assessment, and the individual circumstances of the patients, in order to achieve a balance between therapeutic benefits and the risk of over-treatment. Invasive pathological subtype Although the majority of PTC are of the classic type or follicular subtype, even when combined with LLNM, the prognosis remains relatively good. However, some rare aggressive subtypes show higher risks of recurrence and metastasis, and require more aggressive treatment strategies. Tall‑cell variant PTC displays prominent aggressive features and is frequently associated with advanced age, large tumor size, extrathyroidal extension, and elevated risk of distant metastasis (85). A population‑based study demonstrated that Tall‑cell variant PTC patients had significantly lower 5‑year DSS compared with conventional PTC (83% vs. 98%) (86). Columnar‑cell variant PTC is far rarer yet highly aggressive, with markedly higher rates of LNM and vascular invasion relative to the conventional variant (87). Studies have validated that Columnar‑cell variant PTC serves as an independent risk factor for structural persistent or recurrent disease, with a hazard ratio as high as 4.28 (87). Diffuse sclerosing PTC has a higher rate of lymph node metastasis in the central and lateral cervical regions as well as a higher risk of lung metastasis. Especially in children and adolescents, the rate of lymph node metastasis in the contralateral central and lateral cervical regions is higher, suggesting that it is more aggressive (88,89). The high cell subtype and the hobnail variant are both considered indicators of a poor prognosis. Among these, the hobnail variant exhibits notably rapid growth and a significantly elevated rate of early occurrence recurrence (90-92). For patients with unilateral PTC accompanied by unilateral LLNM, if preoperative fine-needle aspiration or intraoperative frozen pathological examination indicates the possibility of an aggressive subtype, the treatment strategy should prioritize TT combined with more extensive LND and postoperative RAI therapy. Concurrently, a comprehensive postoperative follow-up plan should be developed to minimize the risk of recurrence and optimize patient prognosis. Conclusions Treatment for patients with unilateral PTC accompanied by unilateral LLNM has gradually abandoned the traditional “one-size-fits-all” paradigm and shifted toward risk-stratified individualized therapy. The core principle is to achieve a balance between oncological radicality and functional preservation through comprehensive risk assessment. Objectively, most evidence supporting lobectomy originates from retrospective cohort studies and meta-analyses, largely conducted in highly specialized thyroid-care centers. Substantial selection bias, institutional bias and residual confounding factors exist, and high-level evidence from prospective randomized controlled trials remains lacking. Study subjects were enrolled following strict case screening; therefore, caution should be exercised when extrapolating these conclusions to general medical institutions. Lobectomy should not be simplistically regarded as universally superior to total thyroidectomy. Regarding the extent of thyroidectomy, although domestic and international guidelines still classify N1b disease as an indication for TT, multiple recent studies have demonstrated that LT yields comparable RFS and OS to TT in patients without additional high-risk features. Moreover, LT provides notable advantages in safety and quality of life. Occult malignant lesions in the contralateral lobe can be precisely stratified using relevant risk factors and predictive models. Active postoperative surveillance is safe and feasible for low-risk patients, while the clinical value of RAI therapy has also been questioned. Regarding the strategy for lymph node dissection, most current research indicates that performing CND on the affected side for patients with unilateral PTC presents a significantly lower risk of complications compared to BCND, with no notable difference in oncological outcomes. Concerning lateral cervical lymph nodes, a selective dissection approach targeting level V—based on individual patient risk assessment—can optimize the reduction of surgical trauma while ensuring comprehensive dissection. Furthermore, the quantity of LNY and LNR have gained increasing prominence as vital indicators for evaluating surgical quality and prognostication in clinical practice. Molecular biomarkers and serological markers provide objective evidence for individualized diagnosis and treatment. Serum Tg serves as a core marker for postoperative recurrence surveillance, yet its measurement is interfered by TgAb. BRAF V600E and TERT promoter mutations, particularly their co‑occurrence, indicate aggressive tumor biology with markedly elevated risks of recurrence and death, and are also closely associated with RAI resistance. TT combined with standardized neck dissection is preferentially recommended for patients with dual‑mutation positivity to facilitate subsequent RAI administration and Tg surveillance. By contrast, LT combined with selective neck dissection may be considered for double‑wild‑type patients who lack high‑risk features such as extrathyroidal extension and multifocality. Nevertheless, for aggressive histological variants such as the diffuse‑sclerosing variant, tall‑cell variant, and hobnail variant—particularly in pediatric populations—the combination of TT, BCND, LND, and postoperative RAI therapy may represent the optimal treatment strategy to achieve the most favorable prognosis. Significant opportunities remain for the personalized management of unilateral PTC with unilateral LLNM. First, there is an urgent need for additional high-quality, prospective, multicenter, large-sample randomized controlled trials to further advance individualized treatment protocols for these patients. Second, emerging technologies such as imaging biomarkers and artificial intelligence are anticipated to be integrated more deeply with clinical and pathological data, thereby enabling the development of more precise, dynamic risk prediction models to tailor the most appropriate treatment plans for each patient with unilateral PTC and unilateral LLNM. Supplementary The article’s supplementary files as Available at https://gs.amegroups.com/article/view/10.21037/gs-2026-0281/prf